BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26654068)

  • 1. Antibody-targeted biodegradable nanoparticles for cancer therapy.
    Shargh VH; Hondermarck H; Liang M
    Nanomedicine (Lond); 2016 Jan; 11(1):63-79. PubMed ID: 26654068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents.
    Jia F; Liu X; Li L; Mallapragada S; Narasimhan B; Wang Q
    J Control Release; 2013 Dec; 172(3):1020-34. PubMed ID: 24140748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-targeted liposomes in cancer therapy and imaging.
    Sofou S; Sgouros G
    Expert Opin Drug Deliv; 2008 Feb; 5(2):189-204. PubMed ID: 18248318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for Precise Engineering and Conjugation of Antibody Targeted-nanoparticles for Cancer Therapy.
    Guo YY; Huang L; Zhang ZP; Fu DH
    Curr Med Sci; 2020 Jun; 40(3):463-473. PubMed ID: 32681251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-targeted nanoparticles for cancer treatment.
    Carter T; Mulholland P; Chester K
    Immunotherapy; 2016 Jul; 8(8):941-58. PubMed ID: 27381686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology for targeted cancer therapy.
    Wang MD; Shin DM; Simons JW; Nie S
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):833-7. PubMed ID: 17555393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
    Mattu C; Pabari RM; Boffito M; Sartori S; Ciardelli G; Ramtoola Z
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):463-72. PubMed ID: 23916461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles and targeted drug delivery in cancer therapy.
    Bahrami B; Hojjat-Farsangi M; Mohammadi H; Anvari E; Ghalamfarsa G; Yousefi M; Jadidi-Niaragh F
    Immunol Lett; 2017 Oct; 190():64-83. PubMed ID: 28760499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
    Muthu MS; Singh S
    Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
    Zhong Y; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines.
    Phua KK
    J Immunol Res; 2015; 2015():680620. PubMed ID: 26819957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
    Al-Jamal WT; Kostarelos K
    Acc Chem Res; 2011 Oct; 44(10):1094-104. PubMed ID: 21812415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent trends in targeted therapy of cancer using graphene oxide-modified multifunctional nanomedicines.
    Rahmanian N; Eskandani M; Barar J; Omidi Y
    J Drug Target; 2017 Mar; 25(3):202-215. PubMed ID: 27646598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional superparamagnetic iron oxide nanoparticles: promising tools in cancer theranostics.
    Santhosh PB; Ulrih NP
    Cancer Lett; 2013 Aug; 336(1):8-17. PubMed ID: 23664890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy.
    Du JZ; Mao CQ; Yuan YY; Yang XZ; Wang J
    Biotechnol Adv; 2014; 32(4):789-803. PubMed ID: 23933109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model.
    Karra N; Nassar T; Ripin AN; Schwob O; Borlak J; Benita S
    Small; 2013 Dec; 9(24):4221-36. PubMed ID: 23873835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor.
    Manjappa AS; Chaudhari KR; Venkataraju MP; Dantuluri P; Nanda B; Sidda C; Sawant KK; Murthy RS
    J Control Release; 2011 Feb; 150(1):2-22. PubMed ID: 21095210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy.
    Vivek R; Thangam R; NipunBabu V; Rejeeth C; Sivasubramanian S; Gunasekaran P; Muthuchelian K; Kannan S
    ACS Appl Mater Interfaces; 2014 May; 6(9):6469-80. PubMed ID: 24780315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.